immunotherapy

2 March, 2026

A breakthrough from Aragon opens new avenues of immunotherapy for rare blood diseases

A preclinical study by the IIS Aragón demonstrates, for the first time, the viability of a CAR-T therapy aimed at myeloproliferative neoplasms (rare blood diseases with limited therapeutic options).
25 February, 2026

The Cuenca Villoro Foundation's 2025 Grant supports a project by the IIS Aragón on high-risk neuroblastoma

Endowed with 50.000 euros, this year's call supports the project led by Ariel Gaspar Ramírez Labrada, from the Immunotherapy, Inflammation, Infection and Cancer (I3C) group of the IIS Aragón.
16 April 2025

Julián Pardo Jimeno: “It is essential to collaborate with the right professionals and work in multidisciplinary teams.”

In this interview, the IIS Aragón researcher talks about his work leading the 'Immunotherapy, Inflammation, Infection and Cancer (I3C)' group (GIIS055) and the main challenges they face.
6 February, 2025

A project brings cancer researchers into the classroom

The fifth edition of 'Get to Know Them' by the Spanish Association for Cancer Research (ASEICA) "puts 350 female cancer researchers on the map", ten of them from the IIS Aragón, to reach schools and universities throughout Spain.
September 18, 2024

Luis Alberto Anel Bernal: “A research career, and especially in this field, is a long-distance race that not everyone is suited to”

In this interview, the IIS Aragón researcher talks about his work leading the 'Apoptosis, Immunity and Cancer' Group (GIIS090) and his research interests.